Skip to main content

Table 1 Single agent clinical trials of venetoclax/ABT-199

From: ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development

Clinical trials

Diseases

Responses

References

Phase I

R/R CLL

ORR—79 %

81, 83

Phase Ia

R/R NHL

ORR—48 %

84

Phase II

R/R AML

ORR—15 %

85

New AML

  1. R/R relapsed/refractory, ORR overall response rate, CLL chronic lymphoid leukemia, NHL non-Hodgkin’s lymphoma, AML acute myeloid leukemia